Amoksiklav  400 mg/ 57 mg/5 ml powder for oral suspension בולגריה - בולגרית - Изпълнителна агенция по лекарствата

amoksiklav  400 mg/ 57 mg/5 ml powder for oral suspension

lek pharmaceuticals d.d.. - Амоксицилин и инхибитор на ензима - 400 mg/ 57 mg/5 ml powder for oral suspension

BIOBOS Respi 5 Plus lyophilisate and suspension for suspension  for injection בולגריה - בולגרית - БАБХ (Българска агенция по безопасност на храните)

biobos respi 5 plus lyophilisate and suspension for suspension for injection

„Лекоом“ АД - lyophilisate - live attenuated bovine herpesvirus type 1 (bhv-1), strain bio 27 : ibr ge-negative; suspension – bovine respiratory syncytial virus (brsv) inactivated, strain bio 24; bovine parainfluenza 3 virus (pi3v) inactivated, strain bio 23; bovine viral diarrhoea virus (bvdb) inactivated, strain bio 25; manheimia (pasteurella) hemolytica, inactivated, strain dsm 5283, serotype А1 - инжекционна суспензия - 105.7-107.5 tcid50/ 2ml; rp ≥ 1/ 2ml - говеда

Pentaxim powder and suspension for suspension for injection בולגריה - בולגרית - Изпълнителна агенция по лекарствата

pentaxim powder and suspension for suspension for injection

sanofi pasteur s.a. - Дифтерия, тетанус, коклюш (бесклеточный компонент) и полиомиелит (инактивированная) и haemophilus тип b, конюгирана ваксина (адсорбированная) - powder and suspension for suspension for injection

Cabometyx האיחוד האירופי - בולגרית - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Антинеопластични средства - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.